[go: up one dir, main page]

PE20020833A1 - Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponisibilidad oral - Google Patents

Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponisibilidad oral

Info

Publication number
PE20020833A1
PE20020833A1 PE2002000030A PE2002000030A PE20020833A1 PE 20020833 A1 PE20020833 A1 PE 20020833A1 PE 2002000030 A PE2002000030 A PE 2002000030A PE 2002000030 A PE2002000030 A PE 2002000030A PE 20020833 A1 PE20020833 A1 PE 20020833A1
Authority
PE
Peru
Prior art keywords
paclitaxel
composition
microemulsion
polyoxyl
diglyceride
Prior art date
Application number
PE2002000030A
Other languages
English (en)
Inventor
Walter Morozowich
Ping Gao
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE20020833A1 publication Critical patent/PE20020833A1/es

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) PACLITAXEL; b) UN SURFACTANTE SELECCIONADO DE ACEITE DE RICINO HIDROGENADO POLIOXIL 40, ACEITE DE RICINO HIDROGENADO POLIOXIL 35, ESTERES DE ACIDOS GRASOS POLIOXIETILENADOS SEL SORBITAN, ENTRE OTROS ; c) UN SOLVENTE SELECCIONADO DE POLIETILENGLICOL, PROPILENGLICOL, ETANOL, GLICEROL, ENTRE OTROS Y d) UN POLIMERO CELULOSICO SUSTITUIDO. LA PROPORCION EN PESO DE PACLITAXEL AL SURFACTANTE OSCILA ENTRE 1:5 Y 1:10. LA COMPOSICION CONTIENE ADEMAS UN INHIBIDOR DE LA GLICOPROTEINA P COMO ALGINATO, XANTANO, VERAPAMILO, CICLOSPORINA A Y ADICIONALMENTE UN DIGLICERIDO O UNA MEZCLA DE DIGLICERIDO Y MONOGLICERIDO. LA COMPOSICION GENERA UNA MICROEMULSION SOBRESATURADA DE PACLITAXEL AL ENTRAR EN CONTACTO CON AGUA AUMENTANDO DE ESTA FORMA LA BIODISPONIBILIDAD ORAL DEL FARMACO. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DEL CANCER
PE2002000030A 2001-01-18 2002-01-17 Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponisibilidad oral PE20020833A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26255501P 2001-01-18 2001-01-18

Publications (1)

Publication Number Publication Date
PE20020833A1 true PE20020833A1 (es) 2002-09-19

Family

ID=22998000

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000030A PE20020833A1 (es) 2001-01-18 2002-01-17 Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponisibilidad oral

Country Status (9)

Country Link
EP (1) EP1365759A2 (es)
JP (1) JP2004520398A (es)
AR (1) AR032642A1 (es)
CA (1) CA2434641A1 (es)
MX (1) MXPA03006404A (es)
NZ (1) NZ539046A (es)
PE (1) PE20020833A1 (es)
WO (1) WO2002064132A2 (es)
ZA (1) ZA200305086B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
JP2007506782A (ja) * 2003-09-25 2007-03-22 アクティブバイオティクス インコーポレイティッド リファラジル製剤
SG162798A1 (en) * 2005-06-17 2010-07-29 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
ES2744816T3 (es) * 2006-10-27 2020-02-26 Capsugel Belgium Nv Cápsulas duras de hidroxipropil metil celulosa y proceso de fabricación
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
ES2718090T3 (es) 2010-11-08 2019-06-27 Cadila Pharmaceuticals Ltd Composición farmacéutica de taxoides
CN103110581B (zh) * 2013-02-26 2015-07-22 西南大学 一种紫杉醇微乳药物组合物及其制备方法
KR101542364B1 (ko) 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
CN108136030B (zh) * 2015-07-30 2021-01-26 大化制药株式会社 含有高浓度紫杉烷的用于口服给药的药物组合物
CN107028931A (zh) * 2016-02-04 2017-08-11 上海宣泰医药科技有限公司 一种紫杉醇药物组合物及其药物制剂、制备方法和用途
EP3701943A1 (en) * 2019-02-26 2020-09-02 CAPNOMED GmbH Delayed delivery of anticancer drugs
PE20251285A1 (es) * 2022-05-11 2025-05-14 Lilly Co Eli Composiciones farmaceuticas de glp1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1998013359A1 (de) * 1996-09-24 1998-04-02 Marigen S.A. Ultramikroemulsionen aus spontan dispergierbaren konzentraten mit antitumoral und antiviral wirksamen estern von baccatin-iii-verbindungen
CH688504A5 (de) * 1997-03-26 1997-10-31 Marigen Sa Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit antitumoral wirksamem Taxol und mit Taxol-analogen Verbindungen.
DE69832173T2 (de) * 1997-05-27 2006-08-03 IVAX RESEARCH, INC., Miami Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung
IL133585A0 (en) * 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
IL143580A0 (en) * 1998-12-11 2002-04-21 Pharmasolutions Inc Pharmaceutical compositions containing lipophilic drugs and methods for the preparation thereof
KR100883477B1 (ko) * 1999-05-27 2009-02-16 아쿠스피어 인코포레이티드. 다공성 약물 매트릭스의 약제 조성물
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
AU2002239282A1 (en) * 2000-11-28 2002-06-11 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof

Also Published As

Publication number Publication date
WO2002064132A2 (en) 2002-08-22
JP2004520398A (ja) 2004-07-08
ZA200305086B (en) 2004-06-30
MXPA03006404A (es) 2004-12-02
NZ539046A (en) 2006-11-30
WO2002064132A3 (en) 2003-05-30
CA2434641A1 (en) 2002-08-22
EP1365759A2 (en) 2003-12-03
AR032642A1 (es) 2003-11-19

Similar Documents

Publication Publication Date Title
PE20020833A1 (es) Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponisibilidad oral
AR109354A2 (es) Una composición que comprende un compuesto bicíclico y compuesto
BRPI0511966A (pt) composições farmacêuticas contendo polietileno glicol tendo um peso molecular menor do que 600 daltons
RU2014102013A (ru) Устройство для локальной и/или регионарной доставки с применением жидких составов терапевтически активных веществ
MX373796B (es) Composición de solubilización farmacéuticamente aceptable y forma de dosificación farmacéutica que contiene la misma.
CR20110131A (es) Derivados de prostaglandinas
CR7999A (es) Metodos y composiciones farmaceuticas para la obtencion confiable de niveles aceptables de testosterona en suero
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
CO5570649A2 (es) Producto antitranspirante en gel liquido de alta eficiencia
CO5440227A1 (es) Composicion antihelmitica e inyectable mejorada de crecimiento
ECSP088239A (es) Composición de liberación de fármaco sostenida
AR070033A1 (es) Composiciones inyectables, sus procesos y usos
MA30765B1 (fr) Derives innovants du thiophene
RU2011115418A (ru) Усиление действия противораковых агентов
EA200000703A1 (ru) Сульфонамидные производные в качестве пролекарств, ингибиторов аспартилпротеаз
BRPI0511036A (pt) formulações de solução farmacêuticas contendo 17-aag
MA34296B1 (fr) Composition retard injectable antipsychotique
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
AR046878A1 (es) Agente endoparasiticida para administracion topica
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
CY1105318T1 (el) Φαρμακευτικες συνθεσεις για απο του στοματος και τοπικη χορηγηση
TR200401436T4 (tr) Monotiyogliserol, L-sistem veya tiyoglikolik asitle birlikte pemetrexed içeren farmasötik bileşim
PE20060594A1 (es) Composicion farmaceutica que contiene un agonista de ppar
AR030379A1 (es) Combinaciones

Legal Events

Date Code Title Description
FC Refusal